Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
beta2-solanine
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Oral, Parenteral
01
Overview
Beta2-solanine is a specific **solanine derivative** within the steroidal glycoalkaloid family reported in an *in silico* Alzheimer's disease study. In the provided source, it was evaluated computationally against **acetylcholinesterase** and showed stronger predicted docking affinity than rivastigmine in the modeled receptor system, suggesting a potential **cholinesterase-inhibitory small-molecule** mechanism. However, the evidence provided is limited to computational docking, with no clear clinical development program, product sponsor, formulation, or validated therapeutic use established from the supplied data.
- Other names
- beta2-solaninebeta-2-solaninebeta 2-solanine
02
Targets
Acetylcholinesterase
Beyond the preview
Go deeper on beta2-solanine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on beta2-solanine.